Marino Andrea, Zafarana Gabriella, Ceccarelli Manuela, Cosentino Federica, Moscatt Vittoria, Bruno Gabriele, Bruno Roberto, Benanti Francesco, Cacopardo Bruno, Celesia Benedetto Maurizio
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Nesima Hospital, University of Catania, 95123 Catania, Italy.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.
Diagnostics (Basel). 2021 Dec 11;11(12):2336. doi: 10.3390/diagnostics11122336.
HCV treatment became available for all infected patients regardless of their comorbidities, especially for HIV coinfected subjects, leading to an improvement in both clinical and immunological conditions. We retrospectively analyzed a cohort of HIV/HCV coinfected patients treated with DAA therapies; data regarding epidemiological, viral-immunological, and hepatic parameters before and after DAA administration have been collected. Drug-drug interactions between DAA and both antiretroviral therapy and non-ART-drugs were also evaluated; the study showed the efficacy of DAA schedules in HCV eradication also for HIV/HCV patients with multiple comorbidities and assuming many different drugs. Principal issues are still represented by drug interactions, pill burden, and patients' compliance. These concerns have to be taken into account, especially in HIV patients for whom the immunological state and ART interactions should always be considered.
所有感染丙型肝炎病毒（HCV）的患者，无论其有无合并症，尤其是合并感染人类免疫缺陷病毒（HIV）的患者，都可以接受HCV治疗，这使得临床和免疫状况均得到改善。我们回顾性分析了一组接受直接抗病毒药物（DAA）治疗的HIV/HCV合并感染患者；收集了DAA给药前后的流行病学、病毒免疫学和肝脏参数数据。还评估了DAA与抗逆转录病毒疗法及非抗逆转录病毒治疗药物之间的药物相互作用；该研究表明，DAA方案对于根除HCV也有效，即使是患有多种合并症且正在服用多种不同药物的HIV/HCV患者。主要问题仍然是药物相互作用、药片负担和患者依从性。必须考虑到这些问题，尤其是对于HIV患者，其免疫状态和抗逆转录病毒治疗相互作用始终都应予以考虑。
